Miscellaneous Manufacturing (U.S. NAICS 339): An Investor's Rollup Primer

NAICS (North American Industry Classification System, the U.S. government's standard code for industries) 2022 code 339 — a subsector (three-digit level) that sits at the very bottom of the manufacturing hierarchy. It holds just two child industry groups: 3391 Medical Equipment and Supplies Manufacturing and 3399 Other Miscellaneous Manufacturing. This page synthesizes the two child primers and our ground-truth federal statistics for this level; it does not research from scratch.

---

1. Overview

NAICS 339 is manufacturing's leftover drawer. The classification system carves factories into roughly 20 subsectors — food, chemicals, machinery, transportation equipment, and so on — and 339 is where it puts what did not fit anywhere else. That is why a single three-digit code manages to bracket two things that share almost nothing: a serious, coherent, tightly regulated medical-device industry (3391), and a genuine grab-bag of consumer and industrial niches — jewelry, sporting goods, toys, pens, signs, gaskets, guitars, caskets, candles, slot machines (3399).[1]

So there is no single "miscellaneous manufacturing" market and no single thesis. The distinctive value of reading the two children together is the contrast — one is nearly two-thirds of the subsector, demographically anchored, high-paid, and unusually easy to buy in public markets; the other is a shelf of unrelated niches, mostly private or foreign-owned, that you can only shop one at a time. A few things do hold across the whole subsector, and they are what make it worth an investor's attention as a set:

• Both children are pure manufacturers. Owners earn on the factory stack — units made × price × product mix, minus materials, labor, and overhead. The right questions are about input costs, capacity utilization, brand/spec pricing power, and cyclicality — not utility rate base, real-estate rents, or software subscription metrics.[1]
• Federal factory data understates both. Much of what Americans buy in these categories is imported, and the best-known brands are often booked under other codes — so the ~$162 billion measured here is "what these U.S. factories ship," not the size of the businesses or the end markets.
• The same margin ladder runs through both children, and it sorts by revenue type, not by child. Recurring, specified, or intellectual-property-backed revenue earns a multiple of what commodity, import-facing manufacturing earns — from ~67% and ~69% gross margins at the top (a clear-aligner maker; connected-fitness subscriptions) down to the high-20s, low single digits, and outright losses at the bottom.[2][3] The spread inside each child is wider than the spread between them (Section 5).
• Value migrates the same way in both — toward brands, patents, intellectual property (IP), design, regulatory clearance, and any recurring or aftermarket revenue — and away from undifferentiated commodity output, which domestic plants cannot win on price.
• Tariffs and trade policy are the one lever that touches everything at once, because so much competing supply is imported — and both children now quantify the bill rather than asserting it (Section 7).

The rest of this primer lays out how the two children differ, then treats the subsector as a whole.

---

2. What's inside — the two children and how they differ

NAICS 339 splits one digit down into two industry groups. Both are internally deep: 3391 contains a single five-digit industry (33911) that itself divides into five device sub-industries (surgical instruments, implants, dental equipment, ophthalmic goods, dental labs); 3399 bundles six unrelated industries (jewelry, sporting goods, toys, office supplies, signs, and an "all other" residual that is itself a grab-bag of gaskets, instruments, fasteners, brooms, caskets, and more).[2][3] So the subsector is really eleven distinct end-markets stacked under two headings — but the economically meaningful fault line is the split between the two children.

Here is the core of the rollup: how the two actually compare.

Contrast table — the two children of NAICS 339

Receipts are 2022 Economic Census factory shipments; shares are of the subsector's ~$162B (Section 3). Concentration is the top-4 firms' revenue share (CR4) and the Herfindahl-Hirschman Index (HHI), a 0–10,000 score where below 1,500 is "unconcentrated," both from the 2022 Economic Census.[1] The HHI is federally suppressed for ophthalmic goods and for the toy industry, so none is stated there.[2][3] Note the vintage: several industries inside the other-misc child now also carry newer, differently scoped Annual Integrated Economic Survey (AIES) 2023 figures, which are not interchangeable with the census numbers above (Section 3).[3] DSO = Dental Service Organization; CDMO = contract development and manufacturing organization; PE = private equity; ETF = exchange-traded fund; IP = intellectual property.

Read the table across, and five contrasts define the subsector:

1. It is 60/40 by revenue but 37/63 by factory count. The medical child ships ~60% of the subsector's dollars from just 37% of its establishments; other-misc ships ~40% of the dollars from 63% of the establishments.[1] Medical is fewer, larger, more capital-intensive plants making high-value regulated goods; other-misc is a long tail of smaller shops. Value per establishment runs ~$11 million in medical versus ~$4.4 million in other-misc — a 2.5× gap. The same asymmetry shows in labor: medical is ~55% of the subsector's jobs but ~62% of its payroll.[1][2][3]

2. One child has a master driver; the other has none — but neither is a smooth line. Medical rides a structural, largely non-discretionary driver: aging and chronic disease lift surgical volume, implants, wound care, dental, and vision. Other-misc has no single direction — some pockets grow (sporting goods, toys), one is flat with a hot subsegment (signs/digital LED), one is stable (jewelry), one is in secular decline (office supplies). The revised medical child forces a correction on the old framing, though: "growing" is a statement about the long-run demand curve, not the annual output series. One of its five sub-industries (dental laboratories) is shrinking outright, surgical appliances' real output fell in 2023 as pandemic PPE demand normalized, and U.S. optical volumes and eye exams declined in 2025 even as prices lifted market value.[2]

3. Public investability is night and day — and in 2025–26 the two moved in opposite directions. Medical offers deep, liquid public access through large-cap diversified medtech and device ETFs, and it gained a major listed platform when Medline completed its IPO in December 2025.[2] Other-misc has no pure-play stock and no ETF, in four of its six niches there is no U.S.-listed manufacturer at all, and it lost routes: Light & Wonder left Nasdaq in November 2025, Hillenbrand was taken private in February 2026, Charles & Colvard was delisted in April 2025 and entered Chapter 11 in March 2026, and Callaway sold 60% of Topgolf effective January 2026.[3]

4. Regulation and pay follow the split — but the averages hide a craft trade on each side. Medical is governed by one heavy, unifying regulator (the FDA — the U.S. Food and Drug Administration) and pays skilled cleanroom wages (~$83,500 average, with surgical instruments near $93,000). Other-misc has no single regulator — a scatter of child-specific rulebooks — and pays consumer-manufacturing wages (~$62,000). The subsector average (~$73,900) sits between them and describes neither well.[1][2] The neat wage story breaks down one level deeper: the medical child's dental-laboratory sub-industry is a low-wage, made-to-order craft trade whose technicians averaged about $52,400 in May 2024 — and it is 58% of all firms in the medical child (4,669 of ~7,900), roughly one in five firms in the entire subsector.[2]

5. The economic sorting that matters cuts across the children, not between them. Both children now disclose enough segment economics to line up the same ladder, and it runs by revenue type: recurring, specified, or IP-backed revenue at the top; commodity, import-facing manufacturing at the bottom. Inside medical the spread runs from ~67% gross margin on branded devices to 26–38% in the consumable, contract, and distribution tiers; inside other-misc it runs from ~69% on fitness subscriptions and 53% on gaming-segment EBITDA down to a 2.5% operating margin on licensed toys and a loss-making piano business.[2][3] Knowing which of the two children a business sits in tells you much less than knowing where on that ladder it sits.

---

3. How big it is (the rollup figures, and the undercount)

Federal ground truth (U.S. Census Bureau) for the whole NAICS 339 subsector — we have this level's own ingested statistics, shown below.[1]

The two children add up cleanly — on one vintage. Their reported receipts (~$96.8B + ~$65.1B) total ~$161.9B; their establishment counts (8,825 + 14,801) sum to exactly the subsector's 23,626; their employment (308,388 + 249,509) sums to exactly 557,897; and their annual payrolls (~$25.76B + ~$15.47B) sum to ~$41.24B — useful cross-checks that the rollup is internally consistent.[1][2][3] (Firm counts sum to ~23,727 against the subsector's 23,712; the small gap is deduplication, because a handful of firms operate in both children and are counted once at this level.)

New caution: the cross-check only holds if you hold the vintage. Four industries inside the other-misc child now publish a second, newer federal receipts figure on the 2023 Annual Integrated Economic Survey (AIES) basis — sporting goods at ~$11.58B, toys at ~$1.61B, and, inside the residual, musical instruments at ~$2.39B and the all-other sub-industry at ~$13.1B (that last one on a 2017-NAICS basis).[3] These are differently scoped and differently dated surveys, not corrections, and substituting any of them breaks the tie to ~$65.1B and therefore to ~$161.95B. The medical child reports no such restatement. Read the subsector's ~$162 billion as a 2022 Economic Census number, and resist mixing bases.

The subsector looks more fragmented than either child — and that is an artifact, compounded twice. The pooled HHI of 62.1 and CR4 of 11.5% sit between the two children (medical HHI 164, other-misc HHI 26), and the whole reading is meaningless as a competitive statistic. The dilution happens at every level: each child's pooled HHI is already lower than every one of its own children — all five medical sub-industries are more concentrated than 3391, and all six other-misc industries are more concentrated than 3399 — and stapling a medical-device world to a jewelry-to-slot-machine grab-bag dilutes it once more, because the leader in one niche competes with no one in the others.[2][3] Concentration only means something niche-by-niche — where it runs from oligopoly (four firms hold ~80%+ of U.S. hip and knee implants; a 74.9% casket duopoly) to textbook-fragmented (the sign industry's top four are only ~10%). Read the low subsector HHI as "eleven separate contests," not "easy entry."

The undercount caveat — large, and it runs the same way in both children. These are federal manufacturing statistics: they count U.S. factory output, not what Americans buy or own.

• Imports dominate consumption, and the gap is now measurable on both sides. In medical, one estimate puts roughly 14% of U.S.-marketed medical devices as made in China, about three-quarters of personal protective equipment as imported, and China as the single largest source of eyewear.[2] In other-misc, U.S. jewelry imports run ~$11.5 billion a year against a $7.9 billion domestic base; roughly $10.3 billion of sporting goods were imported in 2024 (~61% from China); and 78–80% of toys sold in America are made overseas, on the order of $17.7 billion.[3]
• The end markets are multiples of the factory base. The broader U.S. medical-device market is estimated near $191 billion (2025), with the U.S. at roughly 46% of global device sales in 2024; The Vision Council valued the 2025 U.S. optical ecosystem at $69.5 billion; and U.S. dental services spending was $189.2 billion in 2024 — all far above the medical child's ~$97 billion of domestic manufacturing.[2] On the other side, U.S. jewelry-and-watch retail alone is ~$63 billion, the U.S. retail toy market is put at ~$45.6 billion for 2025 (of which the directly tracked Circana panel captured $30.3 billion), and the broader U.S. sign, graphics and visual-communications sector is ~$59 billion.[3]
• The best-known brands are often booked elsewhere. Diversified medtech giants straddle this code, the excluded electromedical codes (334510, 334517), and overseas — Align, Dentsply Sirona and Envista alone report worldwide revenue larger than the entire $5.8 billion domestic dental-equipment industry.[2] Toy brand owners that outsource production are classified as wholesalers, and slot-machine makers report under gaming: Light & Wonder's Gaming segment alone booked $2.18 billion of 2025 revenue, more than the entire toy industry's domestic shipments, none of it counted here.[3]
• Small and individual ownership is under-captured. Payroll-based counts miss the thousands of tiny private dental and optical labs and instrument machine shops in the medical child — private "market size" estimates for the dental-lab trade alone range from about $2.4 billion to nearly $8 billion depending on what they bundle in — and the one-person bench jewelers, custom sign shops, luthiers, and craft makers in other-misc.[2][3] Jewelry gives the cleanest measure of the gap: of roughly 35,100 jeweler and precious-stone-and-metal-worker jobs in 2024, 34% were self-employed and only 17% sat inside this manufacturing code, against a payroll count of 19,188.[3]

Net: read $161.95 billion as "what these U.S. factories ship," not "the size of these businesses."

---

4. Investable universe — where value concentrates across the children

The through-line: the two children are almost opposite investment propositions, and the gap widened. Medical is where public, liquid, large-cap access lives; other-misc is where private and foreign ownership dominates and public exposure is thin and indirect. Over 2025–26 the medical child added a listed platform while the other-misc child lost several — so the asymmetry an investor faces today is sharper than it was a year ago.

(a) The medical child (~60% of the subsector) — deep public access, concentrated in two of its five niches. Listed opportunity clusters in the two big device niches — surgical instruments and implants, together ~81% of the medical child — home to the large-cap diversified medtech names and the medical-device ETFs, IHI (0.38% expense ratio) and XHE (0.35%). Those ETFs also hold the excluded electromedical makers, so they are a broad "medtech" bet, not a pure 3391 bet. The three small niches are thin to empty: dental equipment offers only a few near-pure-play mid-caps, ophthalmic goods has no U.S. pure play and no dedicated eyewear ETF, and dental laboratories have essentially no listed play at all beyond one Hong Kong-listed operator. The genuinely new access point is Medline (MDLN), which completed its IPO in December 2025 — the largest U.S. medical-surgical consumables platform at $28.4 billion of 2025 net sales, though roughly half of that is distribution rather than own-brand manufacturing, at a 26.4% consolidated gross margin. Private capital is the mirror image, concentrating exactly where public access is thinnest: contract manufacturers and CDMOs feeding the two surgical niches (a global segment estimated near $89 billion in 2025, still fragmented among several hundred companies), orthopedic, prosthetics and dental-lab roll-ups, and DSO and optical-lab platforms. Specific tickers and platforms are in Section 4 of the 3391 primer.[2]

(b) The other-misc child (~40%) — no pure-play, no ETF, four of six niches with no listed U.S. maker, and routes closing. The only near-pure-play listed manufacturers are in signs (Daktronics, a near-pure-play digital-display maker at roughly $839 million of FY2026 revenue, plus a diversified lighting-and-display firm and a broader identification company) and sporting goods (thin small caps clustered in golf and connected fitness, plus a foreign-domiciled, foreign-controlled global). Everywhere else, public exposure is indirect: toys through public brand/IP owners who outsource the factories; jewelry through demand-side retailers and foreign luxury parents, with the domestic makers private; office supplies as a segment inside diversified brand houses or via foreign listings; and the residual through diversified industrials (seals) and a gaming corner filed under gaming, now reachable only through an Australian listing or U.S. over-the-counter shares. The direction of travel is what is new: Light & Wonder off Nasdaq (November 2025), Hillenbrand taken private (February 2026), Charles & Colvard delisted then in Chapter 11, Topgolf majority sold. Specific names are in Section 4 of the 3399 primer.[3]

Practical takeaway. If you want liquid, listed manufacturing exposure inside NAICS 339, it overwhelmingly means the medical child — bought through diversified medtech and device ETFs, understanding you are really buying a subset of it, and underwriting the relevant product franchise rather than consolidated revenue (the giants book sales across the excluded codes and overseas; roughly half of Medline's revenue is distribution).[2] The other-misc child is largely a private and foreign market with two listed exceptions, and measurably more so than a year ago. There is no ETF for the subsector as a whole, and — given how unrelated a hip implant and a golf club are — no good reason to want one.

---

5. How the money works

Both children are manufacturers, so they share one stack — units × price × product mix, minus materials, labor, and overhead — and deliberately not regulated-utility rate base, real-estate funds-from-operations, or mining all-in sustaining cost. What differs is which profit engine dominates.

• Medical child — razor-and-blades and regulatory moats. The dominant engine is razor-and-blades economics: pair a durable good (a surgical robot, a dental scanner, a lens-fitting system) with a recurring stream of single-use consumables and per-case fees sold again and again against a growing installed base. The revised child sizes it — instruments, accessories, service and leases were $8.5 billion of Intuitive Surgical's $10.1 billion 2025 revenue (84% recurring); more than two-thirds of Stryker's U.S. knee procedures ran on its MAKO robots by end-2025; consumables, service and spare parts are about 70% of Envista's Equipment & Consumables segment. One correction the revised child forces: the old "55–70%+ gross margin" shorthand for this child is too narrow. Branded device makers cluster at 50–67% (Align 67%, Stryker 64%, Envista 55%, Dentsply Sirona 50%), protected by patents, FDA clearance and clinician switching costs — but the consumable, contract and distribution tiers are a different business entirely at 26–38% (ICU Medical 38% in Q4 2025, Medline 26.4% consolidated in 2025). Mixing the tiers into one "medtech margin" is the fastest way to misprice this child. Price is capped by concentrated buyers — hospital Group Purchasing Organizations (GPOs, typically extracting 10–18% off list), the Centers for Medicare & Medicaid Services (CMS) reimbursement schedules, dental DSOs, and vision-insurance plans — and volume, not price, moves the top line even for strong suppliers (Stryker's 2025 constant-currency organic growth was 9.9% volume and only 0.4% price). Two exceptions: dental and premium optical work is largely cash-pay and therefore cyclical, and dental laboratories run a per-unit labor job shop, not razor-and-blades, with payroll on the order of a third of receipts.[2]
• Other-misc child — brand, IP, and mix on a thinner base. No single engine runs across all six niches, but the sharpest shared theme is that value migrates to brand, IP, and design as manufacturing offshores: in toys the money is in owning or licensing IP (licensed toys are now about 37% of the global toy market, and licensed IP pays low-to-mid-teens percent of wholesale), not in running factories; in sporting goods, brands, patents, and pro/tour validation support premium pricing; in jewelry and office supplies, brand and design beat commodity output. Materials are a large share of cost everywhere (precious metals, resins, titanium, wood, LEDs — roughly 60% of production cost for seals), and thin-margin import-facing commodity lines get squeezed first when inputs spike. Recurring revenue exists only in pockets — connected-fitness subscriptions, golf-ball and glove consumables (~40% of one maker's 2025 sales), sign software and maintenance contracts, seal aftermarket, and gaming lease fees that in 2025 exceeded machine sales — and separates the most valuable businesses from the pedestrian ones.[3]

The rollup's central economic finding: one ladder, two children. Both revised children now disclose enough segment economics to rank their businesses, and the two rankings are the same ranking. At the top sit recurring, specified, or IP-backed revenue streams — ~69% gross margin on fitness subscriptions and 53% adjusted-EBITDA margin on a gaming segment in other-misc; ~67% and 64% gross margins on branded devices in medical. At the bottom sit commodity, import-facing lines — a 2.5% operating margin on licensed toys, 7.5% adjusted EBIT on a writing-instruments segment, a loss-making piano business in other-misc; 26–38% in the consumable, contract and distribution tiers in medical.[2][3] The gap along that ladder is roughly an order of magnitude and is larger than the gap between the two children. (These are not comparable statistics — they mix gross, operating and EBITDA margins across different fiscal years and segments that contain more than the NAICS product, and none of them is a NAICS average. The ordering, not the arithmetic, is the point. Note too what is absent: no U.S. jewelry maker discloses a margin at all, because they are private.[3])

Common thread: in both children, the durable prize is a defended position — brand, patent, regulatory clearance, or design — plus any sticky recurring or aftermarket cash flow. The undifferentiated commodity tier gets competed away by imports in both. And in both, a genuine exposure sits beneath the brands: single-customer concentration in the supplier and channel tiers (one medical contract manufacturer disclosed three customers at 49% of 2025 sales; one distributor was 13% of a dental maker's revenue; a toy maker's three largest customers were 42% of global sales).[2][3]

Cyclicality contrasts. The medical child's core volume is largely non-discretionary (you do not defer a needed joint replacement), which makes it the more defensive of the two — but "defensive" is not "smooth," as the 2023 surgical-appliances output decline and 2025 optical-volume decline show.[2] Other-misc is mostly discretionary — jewelry, sporting goods, toys, and premium optical rise and fall with the consumer cycle; signs ride commercial construction and ad spending — and sharply seasonal on top of it (one jewelry retailer's fourth quarter is historically 35–40% of annual sales, setting manufacturers' order books months earlier; one collectibles maker booked 58% of 2025 sales in the second half), with a few famously non-cyclical residual pockets (caskets, cleaning tools).[3]

---

6. Demand drivers

Because the underlying products are unrelated, so are their demand drivers — but they cluster into two families that track the split:

• Medical child — demographics and technology, gated by payment and staffing. The master driver is aging and chronic disease: the U.S. population aged 65 and older rose 9.4% between 2020 and 2023 to roughly 59.2 million, and the Census Bureau projects adults 65+ will outnumber children under 18 beginning in 2029 — lifting surgical volume, joint and spine replacement, wound care, dental restoration, and stronger prescriptions across every niche. Layered on top: technology adoption (minimally invasive and robotic surgery, which consumes more single-use instruments per case; digital dentistry; premium and myopia-control lenses), site-of-care shifts toward lower-cost ambulatory settings, and buyer-structure shifts as DSOs went from about 100 in 2010 to over 2,000, now covering 30%+ of U.S. dentists. The revised child raises two gates that the previous version of this page underweighted: reimbursement and affordability decide which volume is profitable (traditional Medicare covers only one pair of eyeglasses or contacts after cataract surgery; only 45% of the U.S. population saw a dentist in 2022), and access and staffing are a level-wide brake — HRSA counted 70.6 million people in designated dental shortage areas as of March 2026, and the ADA reported in April 2026 that 91% of dentists recruiting hygienists found it extremely challenging. Fewer staffed chairs cap consumable volumes regardless of underlying need. Isolated drivers round it out: the childhood myopia epidemic, adult aesthetics driving clear aligners, single-use-device reprocessing as a substitute, and GLP-1 weight-loss drugs as a two-way wildcard for orthopedics.[2]
• Other-misc child — the consumer and its occasions. Demand tracks discretionary income and confidence (jewelry, sporting goods, toys), life events and gifting (weddings anchor jewelry; holidays anchor toys), participation and hobby trends (247.1 million active Americans in 2024 rising to 250 million in 2025, pickleball at 19.8 million players up 45.8%, 500 million-plus golf rounds a year; the "kidult" collectibles cohort at well over $9 billion a year), demographics and schooling (provisional 2025 births fell 1% to 3,606,400 and the general fertility rate sits 23% below its 2007 level, a structural drag on the infant/preschool toy core), commercial construction and store openings (signs), and digital conversion — cutting both ways (a growth engine for LED signs, a headwind for handwriting-based office supplies). One caution the revised child adds: participation is rising faster than actual outings in outdoor categories, so headline participation overstates gear demand.[3]

Two shared drivers, not one. The first remains tariffs and trade policy, which touch both children at once because so much competing supply is imported — protecting domestic makers on finished goods while inflating imported inputs, and capable of reversing quickly. The second, newly visible in both revised children, is skilled-labor scarcity: cleanroom and dental-lab technicians and unstaffed dental chairs cap volumes in medical, while roughly 42% of sign companies cite staffing as a top concern and bench-jeweler, luthier and premium-seal craft knowledge is thinning in other-misc.[2][3]

---

7. Regulation

The clearest structural contrast in the whole subsector is regulatory: one child has a single heavy regulator; the other has none.

• Medical child — one tight, unifying regime, and its reach is wider than it looks. Nearly everything here is an FDA-regulated medical device, risk-classified I, II, or III. Most products reach market via a 510(k) premarket notification (showing "substantial equivalence" to an existing device, with a De Novo route for novel low-to-moderate-risk products); the highest-risk implants need full Premarket Approval (PMA). Note the terminology trap: "FDA cleared" (510(k)) is not "FDA approved" (PMA). The revised child shows the perimeter is broader than assumed — even ordinary spectacles and sunglasses are devices, and dental laboratories are not comfortably exempt: the custom-device exemption is limited to no more than five units per year of a device type, and a June 2025 warning letter rejected the argument that patient-specific partial dentures made from cleared materials were exempt lab service. Three level-wide currents matter now. The Quality Management System Regulation (QMSR) is in force — effective February 2, 2026, folding in the international ISO 13485:2016 standard, expanding what inspectors may review and raising compliance cost. Sterilization is the newest live constraint and was absent from the previous version of this page: FDA estimates roughly 50% of sterile U.S. medical devices are sterilized with ethylene oxide (EtO), often the only practical method for polymers and catheters; EPA's 2024 emissions rule targeted reductions above 90% at nearly 90 commercial facilities, but EPA proposed repealing it in March 2026, leaving both the rule and sterilizer capacity planning uncertain. And FDA capacity is a watch item after early-2025 federal workforce reductions cut roughly 180 CDRH staff. CMS reimbursement rules — including the mandatory Transforming Episode Accountability Model from January 1, 2026 — gate the profitable volume on top.[2]
• Other-misc child — a scatter of child-specific rulebooks, mostly light on the factory. No single regulator: toys face the Consumer Product Safety Commission (CPSC) and the Consumer Product Safety Improvement Act (mandatory ASTM F963-23 for toys made after April 20, 2024, lead capped at 100 parts per million, phthalates at 0.1%, third-party testing and a Children's Product Certificate — with electronic certificate filing required of importers from July 8, 2026); the same framework plus voluntary standards covers sporting goods, where bicycle helmets are the one federally mandatory rule; jewelry carries Federal Trade Commission (FTC) labeling and sourcing rules, joined now by OFAC's Russian diamond sanctions (third-country-processed stones of at least 1.0 carat barred from March 2024, 0.5 carat from September 2024); signs are lightly regulated to make but heavily regulated as to what can be built and where (zoning, the Highway Beautification Act, First Amendment case law); and niche excise taxes (10% on sport-fishing, 11% on archery) and long-standing antidumping orders (Chinese wood pencils since 1994, Chinese petroleum-wax candles since 1986) dot the group.[3]

The common thread — now with numbers attached: tariffs and trade policy are the shared regulatory swing factor across both children, the one lever that bites the entire subsector at once. In medical, one large maker guided to roughly $400 million of 2025 tariff expense and Medline attributed a 115-basis-point cut to its 2025 gross margin and a $290 million adverse pretax effect to tariffs and related developments; per-device impacts of $2,000–$8,000 on complex devices and combined rates above ~150% on some Chinese optical goods are in play.[2] In other-misc, toy rates spiked as high as 145% in early 2025 before de-escalating to a combined ~17.5% on plush by early 2026, with further Section 301 measures at 12.5% effective July 24, 2026 and the legal footing unsettled (the Court of International Trade ruled the Section 122 component unlawful in May 2026, in force only under a Federal Circuit stay); Section 232 steel and aluminum duties of 25% hit sign fabricators and casket makers on their main input; U.S. music-product companies paid approximately $1.34 billion in tariffs in 2025; and one diversified brand house incurred roughly $174 million of incremental cash tariff cost.[3]

---

8. Consolidation

Consolidation is the default motion in both children, but it runs on different logic, and the subsector's diluted HHI of 62 hides the range entirely.

• Medical child — clearance-driven M&A, financial roll-ups, and now flow in both directions. In the two heavyweights (instruments, implants), incumbents pursue acquire-approved-product-line M&A — buying cleared, revenue-generating portfolios, because FDA clearance, surgeon training, and hospital relationships are the scarce assets (Globus Medical–NuVasive ~$3.1 billion in 2023; Zimmer Biomet–Paragon 28 ~$1.2 billion in 2025). In the three small niches, consolidation runs through financial-buyer roll-ups and take-privates — DSO networks, distributor buyouts (Patterson to Patient Square, ~$4.1 billion, closed April 2025), manufacturer buyouts (ZimVie to ArchiMed, ~$730 million), and dental-lab roll-ups such as the Cerberus-backed platform now at 55+ laboratories. What the revised child adds is the opposite motion: Johnson & Johnson has said it will spin off its DePuy Synthes orthopaedics business (roughly $9.2 billion), Solventum exists only because 3M spun it out, and Medline's December 2025 IPO added a major listed platform — the giants break themselves apart as readily as they bolt things on, and not every deal lands (Alcon's agreed takeover of STAAR Surgical was rejected by shareholders and terminated in January 2026).[2]
• Other-misc child — fragmentation meets private equity, plus brand roll-ups, and the exit door. The fragmented niches (signs, sporting-goods and residual job-shops) are archetypal PE roll-up territory, and the buyer list has widened — regional sign-shop platforms backed by Vestar and CapitalSpring, Watchfire under H.I.G. Capital, Strategic Value Partners taking Revelyst private for $1.125 billion in January 2025 — with the prize being national coverage plus digital capability plus a maintenance annuity. The more concentrated niches (toys, office supplies) consolidate through brand roll-ups (Spin Master's ~US$950 million acquisition of Melissa & Doug, closed January 2024) and a vertical pivot into higher-margin IP and gaming; jewelry is a fragmented base under a concentrated top, with retail consolidation squeezing suppliers.[3]

Common thread, with a new twist. In both children, strong brands, patents, and defended (or FDA-cleared) positions get acquired, while sub-scale commodity makers get squeezed or offshored. But the net effect on public-market supply diverged in 2025–26: the medical child added listed platforms even as it took companies private, while the other-misc child only subtracted — Hillenbrand to Lone Star Funds for ~$3.8 billion, Batesville to LongRange Capital, Light & Wonder off Nasdaq entirely, Charles & Colvard through delisting into bankruptcy. In other-misc, the crown jewels are still migrating from public markets into private and foreign hands, and the migration accelerated.[2][3]

---

9. Risks

Rolled up across NAICS 339, the risks split into a shared stack and child-specific pressures.

Shared across both children:

• Import dependence and offshoring — the structural threat to the commodity tiers of both children, from low-cost devices, frames, and dental restorations to jewelry, toys, and pens.
• Trade-policy whiplash — tariffs help domestic makers on finished goods but inflate imported inputs, and can reverse quickly; both children now carry quantified 2025–26 impacts, and in other-misc the legal footing itself is under appeal.[2][3]
• Buyer bargaining power — pricing sits with concentrated buyers (hospitals, GPOs taking 10–18% off list, CMS, DSOs, and vision plans in medical; mass merchants, clubs, dollar stores, and national retail/QSR programs in other-misc, where one toy maker's three largest customers were 42% of 2025 global sales).[2][3]
• Customer and channel concentration beneath the brands — contract manufacturers, distributors, and insourceable DSO contracts in medical; retailer dependence and private label in other-misc.
• Skilled-labor scarcity — cleanroom and dental-lab technicians on one side, bench jewelers, sign fabricators, and craft trades on the other.
• Investor-access risk — public exposure is uneven (concentrated in two medical niches) or largely absent (four of six other-misc niches), so a clean "339" thesis cannot be expressed — and in other-misc it got measurably harder to express in 2025–26.

Medical-child-specific: regulatory, recall, and product-liability exposure, heaviest in implanted and invasive products; reimbursement squeeze; ongoing compliance cost from the now-in-force QMSR; a sterilization bottleneck new to this page, where roughly half of sterile devices depend on ethylene oxide and any capacity loss or hurried transfer can interrupt supply outright; sole-source input dependence; and technology disruption sharpest in dental labs, the one sub-industry whose domestic pie is flat-to-shrinking as dentists mill and print chairside and offshore labs undercut on price.[2]

Other-misc-child-specific: discretionary, cyclical, and sharply seasonal demand; fad- and hit-driven volatility (the connected-fitness boom-bust is the cautionary tale, and toys' 2025 growth was narrow); input-cost swings against thin margins; product-safety and recall exposure sharper than the child's size suggests, because so many products are aimed at children (a single 2025 helmet action covered about 201,200 units; the July 2026 toy eFiling requirement raises the cost of weak supplier traceability); and structural declines in individual niches (digitization erodes handwriting; falling birth rates drag the toy core; BLS projects jeweler employment down 5% from 2024 through 2034).[3]

One correction the revised children force on any rollup at this level: demand is not a smooth line, even where it trends up. "Healthcare demand always rises" is an inadequate forecasting rule for the medical child — surgical appliances' real output fell about 8.2% from 2022 to 2023 as pandemic PPE demand normalized, and U.S. optical volumes and eye exams declined in 2025 even as higher prices lifted market value. The long-run demand curve and the year-to-year output series are different things in both children.[2][3]

---

10. How to invest & outlook

There is no way to buy NAICS 339 as such — no ETF, no index, no pure-play stock, and (given that the subsector staples a medical-device industry to a jewelry-to-slot-machine grab-bag) no good reason to want one. The subsector is a statistical residual, not an investment. The sensible approach is to pick the child whose economics you like — and, one level finer, the rung on the margin ladder you want (Section 5) — and enter through the route that child allows.

If you want a clean, demographically anchored, publicly investable manufacturing exposure → the medical child. Public-market investors get the deepest, most liquid access in the whole subsector through diversified medtech large-caps and the medical-device ETFs IHI and XHE (understanding those are a broad "medtech" bet that also holds excluded electromedical names, not a pure 3391 bet), plus, since December 2025, Medline. Underwrite the relevant product franchise rather than consolidated revenue — the giants book sales across the excluded codes and overseas, and roughly half of Medline's revenue is distribution. Private-market investors get disproportionate access to the supplier tiers and the three small niches — contract manufacturers and CDMOs, orthopedic, prosthetics and dental-lab roll-ups, DSO and optical-lab platforms. The diligence questions converge: recurring/consumable mix and installed-base pull-through, FDA pathway and inspection history, recall exposure, customer concentration, sole-source inputs and sterilization dependence, validated capacity, and technician retention in the craft trades.[2]

If you want the consumer and niche-industrial brands → the other-misc child, one niche at a time. The only near-pure-play listed makers are in signs and sporting goods; everywhere else you are pushed toward brand/IP owners (toys), demand-side retailers and foreign luxury parents (jewelry), diversified brand houses or foreign listings (office supplies and the residual), or private ownership — and more so than a year ago. Most of this child actually trades as lower-middle-market private roll-ups (fragmented sign shops typically around 3–5× earnings) and brand/licensing buyouts. The diligence question that repeats across all six niches: separate real manufacturing from resale of imported goods, and separate genuine recurring revenue from ordinary repeat orders.[3]

(Reserve valuation, yield, and multiple judgments for a security-specific screen; specific tickers live in the two child primers.)

Outlook (forward-looking judgment, not fact). Expect the two children to keep diverging, not converging:

• The medical child is the subsector's durable, demographically anchored growth core (~60% of receipts) and the only part with deep public access. The structural case — aging, chronic disease, minimally invasive and robotic surgery, digital dentistry, the myopia epidemic — should keep unit volumes and recurring revenue growing at a mid-single-digit pace, faster in niches (clear aligners ~15%/yr, dental implants ~8.5%/yr, advanced wound care mid-to-high single digits). Two honest caveats belong alongside it: dental laboratories are the exception to the growth story, and the annual output series is lumpier than the demand curve. The near-term swing factors are policy and cost, not demand — how far tariffs compress margins, whether FDA review capacity and the now-in-force QMSR hold up, whether ethylene-oxide sterilization capacity stays available while EPA reconsiders its 2024 rule, and how hard consolidated buyers squeeze price. This is a policy- and trade-exposed manufacturing level, not a purely defensive one.[2]
• The other-misc child stays a shelf of unrelated niches with no shared trend — sporting goods the most structurally favorable on record participation, toys' 2025 recovery real but narrow and hostage to tariff resolution, digital-LED signs the standout inside a flat industry, jewelry a stable niche reshaped by elevated gold and lab-grown stones, office supplies in secular decline, and the residual mixed with high-value seals and gaming as the bright spots — and thin, mostly indirect public access that shrank rather than grew. Its near-term swing factors are tariffs, the consumer cycle, fad durability, and, for premium seals, PFAS regulation.[3]

The single most reliable conclusion from rolling the two together: NAICS 339 is not one industry but two very different ones sharing a leftover code. Nearly two-thirds of it — the medical child — is a coherent, demographically anchored, publicly investable business; the rest is a private, foreign, and fragmented grab-bag you buy niche by niche or not at all. The revised children sharpen that with a second conclusion that cuts the other way: within both children, what actually separates a good business from a pedestrian one is not the code but the revenue type — recurring, specified, or IP-backed at the top of the ladder, commodity and import-facing at the bottom. For an investor, "miscellaneous manufacturing" is less a subsector to buy than a label to see through.

---

Sources

1. U.S. Census Bureau, 2022 Economic Census (receipts, firm counts, concentration ratios CR4/CR8/CR20/CR50, HHI) and County Business Patterns 2023 (establishments, employment, annual and first-quarter payroll), NAICS 339 and its child industry groups 3391 and 3399. Our ingested federal ground-truth statistics for this subsector, and the federal figures underlying each child primer. Note that several industries beneath 3399 now also carry restated receipts on the Annual Integrated Economic Survey 2023 basis, which is not interchangeable with the 2022 Economic Census vintage used here. https://www.census.gov/programs-surveys/economic-census.html; https://www.census.gov/programs-surveys/cbp.html
2. Histometrics child primer, NAICS 3391 — Medical Equipment and Supplies Manufacturing (a single-child pass-through to leaf 33911, itself split into surgical instruments 339112, surgical appliances and implants 339113, dental equipment 339114, ophthalmic goods 339115, and dental laboratories 339116), synthesizing U.S. Census (2022 Economic Census / 2023 County Business Patterns) figures, sub-industry concentration (HHI 173.1 to ~665; ophthalmic CR4 59.3% / CR8 73.3%), BLS wage and employment projections (dental-lab technicians $52,400 mean May 2024; 35,200 in 2024 → 33,600 in 2034) and output data (surgical appliances −8.2% 2022→2023), FDA device-regulation pathways (510(k), De Novo, PMA), the QMSR effective February 2, 2026, FDA and EPA ethylene-oxide materials (2024 rule and 2026 proposed repeal), the June 2025 warning letter on custom dental devices, CMS reimbursement and National Health Expenditures (U.S. dental services $189.2B in 2024), HRSA and ADA access and staffing data, The Vision Council's 2025 U.S. optical estimate ($69.5B), the broader U.S. medical-device market (~$191B, U.S. ~46% of global sales), company filings (including Medline's 2025 Form 10-K — $28.4B sales, 26.4% gross margin, $290M tariff impact — and disclosures from Intuitive Surgical, Stryker, Align, Envista, Dentsply Sirona, ICU Medical and Integer), tariff analyses, ETF fund documents, and 2023–2026 M&A, IPO and spin-off activity. Internal.
3. Histometrics child primer, NAICS 3399 — Other Miscellaneous Manufacturing and its six children (jewelry 33991, sporting goods 33992, toys 33993, office supplies 33994, signs 33995, and the residual 33999), synthesizing U.S. Census (2022 Economic Census / 2023 County Business Patterns / 2023 Annual Integrated Economic Survey) figures, retail and end-market benchmarks (U.S. jewelry-and-watch retail ~$63B; U.S. retail toy market ~$45.6B for 2025 with a $30.3B tracked panel, +6%; broader U.S. sign and visual-communications sector ~$59B), import and tariff data (jewelry ~$11.5B; sporting goods ~$10.3B, ~61% from China; toys 78–80% imported), SFIA, National Golf Foundation and USTA participation data, CDC provisional birth data, segment margin disclosures across Peloton, Light & Wonder, Acushnet, Hasbro, Enpro, ACCO, JAKKS, Daktronics, Escalade, YKK, Société BIC and Kawai, CPSC/CPSIA/ASTM, FTC and OFAC regimes, antidumping orders, and 2024–2026 delisting, take-private and roll-up activity. Internal.